ApoB

There are 48 papers on ApoB in aging research: 10 trials and 28 observational studies in people, 2 in animals, 1 in cells, 6 reviews. The newest story, Nov 9, 2026: “Weighted blood marker better predicted heart and stroke risk”.

Biomarker

48 papers study it22 findings

14 new papers in 30 daysSee all 48 papers on ApoB

At a glance

A human study links ApoB to cardiovascular disease risk; another reports lower ApoB three to five years after sleeve gastrectomy in people with obesity. A review describes ApoB as a predictor of cardiovascular risk and the adequacy of risk-lowering therapy compared with LDL-C or non-HDL-C.

22 findings in 20 papers from 2017 to 2026, 5 of them since June 2026

“RHR were about two-fold stronger in younger (<50 years) compared with older individuals (≥65 years), particularly ApoB (RHR 2.12 [95% CI 1.81-2.48])”
Lipid markers and age differences in atherosclerotic cardiovascular disease riskESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.3376
  • Human trial10
  • Humans28
  • Animals2
  • Cells1

Interventions

3

Inclisiran

downin humans1−37%

1 study
  1. Inclisiran decreases ApoB in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-36.84%).

    “nonhigh-density lipoprotein cholesterol, -40.57%; apolipoprotein B, -36.84%”

    Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207

    Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial

    Journal of clinical lipidology

More on Inclisiran

Laroprovstat

downin humans1

1 study
  1. Laroprovstat decreases ApoB in humans.

    “Decreased levels of ApoB, ApoE, and Apo(a) were also detected with the ApoEdgeTM method.”

    Human trial

    Laroprovstat (AZD0780) an oral, small molecule PCSK9 inhibitor demonstrates improvements in the lipid profile in participants with hypercholesterolemia: Results from a Phase 1 study

    AHA Scientific Sessions 2025 abstract

More on Laroprovstat

Mixed nuts

downin humans1

1 study
  1. Mixed nuts decrease ApoB in humans (−0.07 g/L (95% CI: −0.12 to −0.02)).

    “Plasma apoB concentrations (−0.07 g/L; 95% CI: −0.12 to −0.02; p = 0.009) and the apoB/apoA1 ratio (−0.05; 95% CI: −0.08 to −0.01; p = 0.009) were also significantly reduced.”

    Human trial16 weeksn = 28

    Effects of Longer-Term Mixed Nut Consumption on Lipoprotein Particle Concentrations in Older Adults with Overweight or Obesity

    Nutrients

More on Mixed nuts

Effects

2

Cognitive impairment

no changein humans1OR 1.003

1 study
  1. ApoB was not clearly linked with cognitive impairment in humans (unadjusted logistic regression) (OR 1.003 (95% CI 0.998–1.008)).

    “no significant association between ApoB and CI (OR: 1.003, 95% CI: 0.998–1.008, p = 0.215)”

    Humansunadjusted logistic regressionn = 1,105

    Association between LDL‐C/ApoB Ratio and Cognitive Impairment: a retrospective study of NHANES

    AAIC 2025 abstract

More on Cognitive impairment

Bruch's membrane lipoproteins

upin humans1

1 study
  1. ApoB is linked with higher Bruch's membrane lipoproteins in humans (compared with donor plasma HDL from the same individuals).

    “The most striking difference is higher concentrations of ApoB and ApoE, which bind to glycosaminoglycans.”

    Humanscompared with donor plasma HDL from the same individualsBruch's membrane

    High-density lipoproteins are a potential therapeutic target for age-related macular degeneration

    The Journal of biological chemistry

Upstream

1

APOE

downin humans1

1 study
  1. APOE is linked with lower ApoB in humans (carriers of the APOE2 allele) (p < 0.05).

    “confirmed strong overexpression of BIRC2 (p < 5E-16) and under-expression of APOB in carriers of the APOE2 allele (p < 0.05)”

    Humanscarriers of the APOE2 alleleserum

    Effect of longevity genetic variants on the molecular aging rate

    GeroScience

More on APOE

Associations

15

APOE

mixedin humans2

2 studies
  1. APOE is associated with ApoB in humans (e2 allele).

    “This analysis replicated the association between APOB and the e2 allele of APOE”

    Humanse2 allele

    A Robust Serum Proteomic Signature of the E2 Allele of Apolipoprotein E

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  2. APOE is associated with ApoB in humans (Pinteraction = 9.0e - 14).

    “rs429358 (tagging APOE4) was identified for ApoB (Pinteraction = 9.0e - 14)”

    Humansrs429358 (tagging APOE4); gene-age interaction; genetic effect closer to null with increasing age

    Large-scale genome-wide interaction analyses on multiple cardiometabolic risk factors to identify age-specific genetic risk factors

    GeroScience

More on APOE

Maternal supraphysiological hypercholesterolemia

upin humans1

1 study
  1. Maternal supraphysiological hypercholesterolemia is associated with ApoB in humans (Women who subsequently developed maternal supraphysiological hypercholesterolemia).

    “Women who subsequently developed MSPH also showed higher first-trimester ApoB and malondialdehyde.”

    HumansWomen who subsequently developed maternal supraphysiological hypercholesterolemiaFirst trimesterfemalesn = 78

    Early Detection of Maternal Supraphysiological Hypercholesterolemia: Development and Internal Validation of a Machine Learning Model and Characterization of First- Trimester Atherogenic Biomarkers

    Research SquarePreprint

More on Maternal supraphysiological hypercholesterolemia

Atherosclerotic cardiovascular disease risk

upin humans1

1 study
  1. ApoB is associated with atherosclerotic cardiovascular disease risk in humans (Ratio of hazard ratios 2.12 (95% CI 1.81–2.48), younger versus older individuals).

    “RHR were about two-fold stronger in younger (<50 years) compared with older individuals (≥65 years), particularly ApoB (RHR 2.12 [95% CI 1.81-2.48])”

    HumansStronger association in younger versus older individuals; free of cardiovascular disease and not using cholesterol-lowering medications at baselineMedian follow-up 13.2 yearsn = 401,228

    Blood fat markers show stronger artery disease links at younger ages

    ESC Congress 2026 abstract

Major adverse cardiovascular events

upin humans1

1 study
  1. ApoB is linked with a higher risk of major adverse cardiovascular events in humans (men versus postmenopausal women) (10.88% versus 4.34% 10-year MACE risk).

    “At age 58, ApoB ≥1.2 g/L conferred 10.88% versus 4.34% 10-year MACE risk in men versus postmenopausal women”

    Humansmen versus postmenopausal women

    Heart risk models overestimated risk after menopause

    Journal of clinical lipidology

More on Major adverse cardiovascular events

Ischemic heart disease

upin humans1HR 1.125

1 study
  1. ApoB is associated with ischemic heart disease in humans (HR 1.125 [1.104-1.146]).

    “ApoB tracked ischaemic heart disease (HR 1.125 [1.104-1.146]) but not heart failure.”

    Humansfemales

    Heart risk models overestimated risk after menopause

    Journal of clinical lipidology

More on Ischemic heart disease

Coronary artery calcium

upin humans1OR 1.74

1 study
  1. ApoB is associated with coronary artery calcium in metabolically healthy obesity with discordantly high apoB (OR 1.74 (95% CI, 1.13-2.66)).

    “MHO with discordantly high apoB showed increased CAC progression risk (OR, 1.74; 95% CI, 1.13-2.66)”

    Humansin metabolically healthy obesity with discordantly high apoBcoronary arterymedian follow-up of 6 yearsn = 15,738

    Apolipoprotein B-low-density lipoprotein cholesterol discordance refines cardiovascular risk stratification across metabolic phenotypes

    Journal of clinical lipidology

More on Coronary artery calcium

Cardiovascular disease

upin humans1

1 study
  1. ApoB predicts cardiovascular disease in humans (review of risk predictors).

    “The importance of apolipoproteinB (apoB) and lipoprotein A (LpA) as better risk predictors than just elevated LDL levels will be emphasized”

    Reviewreview of risk predictors

    Evaluating Cardiovascular Disease Risk

    Journal of insurance medicine (New York, N.Y.)

More on Cardiovascular disease

Pathogenic FH-associated variants

upin humans1

1 study
  1. pathogenic FH-associated variants are associated with ApoB in humans (genetically confirmed FH versus variant-negative patients) (significantly higher (p=0.001)).

    “Genetically confirmed FH patients exhibited significantly higher levels of ApoB (p=0.001) compared with variant-negative individuals”

    Humansgenetically confirmed FH versus variant-negative patients

    Biochemical characterisation of familial hypercholesterolemia: Associations between genetic and lipid profiles

    Journal of medical biochemistry

P53

upin humans1

1 study
  1. ApoB is associated with P53 in humans (r=0,55).

    “ApoB and p53 (r=0,55)”

    Humans

    The role of lipid metabolism disorders in the activation of cellular aging markers in atherosclerosis in elderly and senile individuals

    Advances in gerontology = Uspekhi gerontologii

More on P53

Discordant LDL-C elevation

upin humans1

1 study
  1. ApoB is associated with discordant LDL-C elevation in humans among adults reaching equivalent apoB goals of <55, <70, and <100 mg/dL (up to 61%, 56%, and 49%).

    “among those reaching apoB goals of <55, <70, and <100 mg/dL, LDL-C was discordantly elevated in up to 61%, 56%, and 49%, respectively”

    Humansamong adults reaching equivalent apoB goals of <55, <70, and <100 mg/dLn = 298,578

    Treatment Implications of LDL-Cholesterol and Apolipoprotein B Discordance: Insights from the Very Large Database of Lipids (VLDbL) and the National Health and Examination Survey (NHANES)

    AHA Scientific Sessions 2025 abstract

More on Discordant LDL-C elevation

All 15

Funding

1 grant since 2026

National Heart, Lung, and Blood Institute$310K

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 6Feb 2026: 2Mar 2026: 2Apr 2026: 1May 2026: 0Jun 2026: 1Jul 2026: 1Aug 2026: 1Sep 2026: 0Oct 2026: 12Nov 2026: 531 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Weighted blood marker better predicted heart and stroke risk

Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.

Randomized trial · 11,957 peopleBiomarkers
ESC Congress 2026 Abstract

Enlicitide lowered bad cholesterol across cardiovascular risk groups

A pooled analysis of two randomized trials in 3,212 people found lower bad cholesterol with enlicitide than placebo across cardiovascular risk groups.A pooled analysis of two randomized trials in 3,212 people found lower bad cholesterol with enlicitide than placebo across cardiovascular risk groups.

Meta-analysis · 3,212 peopleEnlicitide
ESC Congress 2026 Abstract

Recaticimab lowered cholesterol with or without coronary disease

A pooled analysis of four randomized trials in 1,120 people with high blood fats found reductions versus placebo after 12 or 16 weeks.A pooled analysis of four randomized trials in 1,120 people with high blood fats found reductions versus placebo after 12 or 16 weeks.

Meta-analysis · 1,120 peopleInterventions
ESC Congress 2026 Abstract

Blood fat markers show stronger artery disease links at younger ages

Disease links for several blood fat markers were about twice as strong below age 50 as at age 65 or older.Disease links for several blood fat markers were about twice as strong below age 50 as at age 65 or older.

Cohort · 401,228 peopleBiomarkers

See all 48 papers on ApoB